1. Home
  2. Products
  3. Customized ADCs
  4. NCA-90
  5. Anti-NCA-90 (Lemalesomab)-MC-MMAF ADC

Anti-NCA-90 (Lemalesomab)-MC-MMAF ADC (CAT#: ADC-W-2164)

This ADC product is comprised of an anti-NCA-90 monoclonal antibody conjugated via a MC linker to MMAF. The MMAF is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAF binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.

  • ADC Target
  • ADC Antibody
  • ADC Linker
  • ADC payload drug
  • Name
  • NCA-90
  • Alternative Names
  • NCA-90
  • Overview
  • One of the nonspecific cross-reacting antigens found to be expressed on a variety of cell types. In the nomenclature of CD antigens this protein has been given the designation CD66a. NCA-90 and NCA-50 have the same sequence and the same placement of glycosylation sites despite their differences in molecular masses.
  • Overview
  • Humanized Anti-NCA-90 IgG1 antibody, Lemalesomab
  • Generic name
  • Lemalesomab
  • Host animal
  • Mouse
  • Name
  • MC (maleimidocaproyl)
  • Description
  • Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.
  • Name
  • MMAF
  • Description
  • Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.

For Research Use Only. NOT FOR CLINICAL USE.

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-W-2164. Click the button above to contact us or submit your feedback about this product.

Quick Links

Other Products

Same Target Same Linker Same Payload
CAT# Product Name Linker Payload
ADC-W-2167 Anti-NCA-90 (Lemalesomab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC MC-Vc-PAB-DMEA-(PEG2) duocarmycin SA
ADC-W-2163 Anti-NCA-90 (Lemalesomab)-SPDB-DM4 ADC SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine)
ADC-W-2162 Anti-NCA-90 (Lemalesomab)-SMCC-DM1 ADC SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine)
ADC-W-2166 Anti-NCA-90 (Lemalesomab)-MC-Vc-PAB-SN38 ADC MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) SN-38 (7-ethyl-10-hydroxycamptothecin)
ADC-W-2165 Anti-NCA-90 (Lemalesomab)-MC-Vc-PAB-MMAE ADC MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) MMAE
CAT# Product Name Linker Payload
ADC-W-322 Anti-CD19 (clone hBU12)-Mc-MMAF ADC Mc (maleimidocaproyl) MMAF (Monomethyl auristatin F)
ADC-W-478 Anti-ENPP3-Mc-MMAF ADC Mc (maleimidocaproyl) MMAF (Monomethyl auristatin F)
ADC-W-491 Anti-TNFRSF17-Mc-MMAF ADC Mc (maleimidocaproyl) MMAF (Monomethyl auristatin F)
ADC-W-485 Anti-EphA2 (clone 1C1)-Mc-MMAF ADC Mc (maleimidocaproyl) MMAF (Monomethyl auristatin F)
ADC-W-517 Anti-TM4SF1 ( clone v1.10)-Mc-LP2 ADC Mc (maleimidocaproyl) LP2 (chemical name mc-3377)
CAT# Product Name Linker Payload
ADC-W-2573 Anti-SLC34A2 (Lifastuzumab )-MC-MMAF ADC MC (maleimidocaproyl) MMAF
ADC-W-2556 Anti-CD79B (Polatuzumab )-MC-MMAF ADC MC (maleimidocaproyl) MMAF
ADC-AA-063 Anti-HIgG(Fab)-N-MMAF ADC Noncleavable linkers MMAF
ADC-W-2606 Anti-ITGB3 (Tadocizumab)-MC-MMAF ADC MC (maleimidocaproyl) MMAF
ADC-W-2622 Anti-NCAM1 (Lorvotuzumab )-MC-MMAF ADC MC (maleimidocaproyl) MMAF

Online Inquiry

Name:
*Phone:
*E-mail Address:
*Products or Services Interested:
Company/Institution
Project Description:

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.